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Northern Ireland,0 T 0T14TUnited Kingdom 12 18 The roadmap for antibody production with high efficiency is already explicated by nature: studies 19 of how the immune system's B cells differentiate into antibody-secreting plasma cells provide a 20 comprehensive blueprint of the factors needed to equip the cell for complex protein production. 21
The most striking feature of these professional secretors is their extensive endoplasmic reticulum 22
(ER), which fills most of the cytoplasm. Accordingly, many of the biochemical activities of the 23 4 ER are upregulated during differentiation, including the abundance of folding factors, such as 1 chaperones, co-chaperones, protein disulfide isomerases (PDIs), and peptidyl-prolyl isomerases 2 (PPIases) [12] [13] [14] . Overexpression of folding factors, most notably PDI and the chaperone BiP, 3
have been studied in recombinant protein production for over two decades in different expression 4 systems amongst others including yeasts, insect cells and mammalian cells [15] [16] [17] [18] [19] . In the case of 5 antibody production in S. cerevisiae, overexpressing PDI (Pdi1p) and BiP (Kar2p), and ER 6
engineering have been effective strategies in several occasions [8, 9, 20] . 7 8
Previously, we demonstrated that following the example of plasma cells by increasing the size of 9 ER prior to protein expression, through deletion of the lipid regulator gene OPI1, is beneficial for 10 antibody production in S. cerevisiae [9] . Mimicking steps in B cell differentiation has been 11
proposed as an engineering strategy for mammalian cell platforms and interestingly, in yeast the 12 strategy has been exploited in expanding antibody diversity [21, 22] . In this study, we further 13 explore the use of plasma cells as a blueprint for the development of a S. cerevisiae antibody 14 factory by co-expressing a comprehensive set of mammalian derived ER folding factors together 15 with a full-length IgG in yeast. We screened constructs for expression of ten folding factors shown 16
to interact with nascent antibodies in their endogenous environment and identified elements 17 beneficial for improving IgG titers in yeast. We show that the improvements of the engineered 18 strains were specific for recombinant mammalian proteins, as the effects were similar with human 19 erythropoietin but absent in expression of the endogenous yeast acid phosphatase. Although the 20 yeast PPIase Cpr5p expressing strain generated the highest antibody titers, we demonstrate that 21 mammalian folding factors can successfully be used in engineering of folding in yeast. 22 23 5 2 Materials and methods 1
Enzymes used for DNA amplification and manipulation were purchased from Thermo Fisher 2 Scientific (Vantaa, Finland). Media components and reagents were obtained from Sigma-Aldrich 3 (Helsinki, Finland) unless stated otherwise. 4
2.1 Yeast strains 5
As described in detail in [9] , two yeast strains served as the basic chassis in all screening 6 experiments: W303α and W303α∆opi1, from here on referred to as wt and ∆opi1, respectively. 7
Both strains harbor a single copy of the light and heavy chain encoding genes of the monoclonal 8
antibody C2B8 under control of the GAL1-promoter integrated to the genomic HIS3-site. 9
The acid phosphatase gene (PHO5) and cDNA for human EPO (Source Bioscience, clone 10
OHu20340) were cloned under PR GAL1 Rinto the integrative pRS305K-plasmid [23] . PR GPDR -PHO5-11 cyc1 cassette from plasmid pAX391 [24] was inserted between SmaI and BssHII sites of the 12 pRS305K-backbone creating plasmid pAX401. PR GPDR was replaced with a PCR amplified PR GAL1R 13 promoter (oligonucleotides 28 and 29, Supporting information, ERp72. Human PDI cDNA was from Dr. Neil Bulleid. cDNA for human BiP was obtained from 5
Source Bioscience (IMAGE clone 5020098). The used oligonucleotides are presented in 6
Supporting information, Table S1 . 7
The selected cDNAs were cloned into the low-copy number yeast shuttle vectors pRS415 and 8 pRS416 [26] under GAL1 (PR GAL1R ), GPD (PR GPDR ), and TEF (PR TEFR ) promoters and under the UPR-9
controlled promoters derived from the PDI1 (PR PDI1R ) and KAR2 (PR KAR2R ) genes, as described in [9]. 10
Native ER targeting signals were used for all genes except P5, which had the leader peptide from 11 yeast PDI [25]. Oligonucleotides 1 and 2 were used to amplify cDNA for human BiP replacing the 12 human ER retrieval sequence with the yeast sequence. Vectors and insert were both digested with 13
SpeI and XhoI and T4 ligase was used for fragment ligations generating plasmids with BiP under 14 control of PR GAL1R , PR GPDR , and PR TEFR . The ERdj3 insert was amplified with oligonucleotides 3 and 4 15 so that the fragment ends contained Eco31I sites. The oligonucleotides were designed so that after 16 digestion of the insert with Eco31I the sticky ends became compatible with SpeI and XhoI sites, 17
which were used to cut the vectors.
18
The cloning of P5 and GRP94 to pRS41X-vectors is described in [25] . Other cDNAs were cloned 19 into pRS41X-vectors using ELIC [25]: the cDNAs were amplified in the first round of PCR with 20 gene specific oligonucleotides. An adaptor sequence of 16 bp was added to the 5' end. The yeast 21 specific ER retrieval signal (HDEL) was either mutated in the original gene sequence (GRP94, 22
PDI, GRP170, P5, BiP), or inserted at the C-terminal end of the genes (ERdj3, ERp57, ERp72, 23 FKBP2, CypB). If HDEL resulted from mutation, the first round of PCR introduced a 17 bp 1 adaptor sequence to the 3' end. In case of HDEL insertion, an additional round of PCR was used 2 to add the 3' adaptor sequence by using gene specific 5' oligonucleotide and oligonucleotide 3 number 19 to add the adaptor sequence to 3' end. The last round of PCR introduced complementary 4 ends to the plasmids (adaptor specific oligonucleotides number 20 and 21-25). BiP cDNA was 5
introduced under PR KAR2R and PR PDIR by amplifying the gene with oligonucleotides 26 and 27 thus 6
adding the adaptor sequence only to the 5' end. All amplified coding sequences were cloned into 7
linearized vectors with ELIC [25]. The destination vectors were linearized with SpeI and XhoI as 8 above, except for plasmids containing PR KAR2R where XbaI and XhoI were used. Plasmids were 9
transformed into the yeast strains using the lithium-acetate method [27] . Control strains contained 10
only the empty vectors to complement the auxotrophies. 11
Screening process and cultivation of yeast strains 12
Screening the yeast strains was conducted in deep-well plate format as outlined in [9] . Briefly, the 13 saturated pre-cultures of ODR 600R between 5 and 10 were diluted 1:4 in fresh SD-URA-LEU media, 14 which contained 2 % raffinose, and grown at 30 ˚C, 250 rpm for 5.5 hours before protein 15 expression was induced by adding galactose to a final concentration of 0. at least three biological replicates. 21
Cultivations of EPO and acid phosphatase expressing strains were conducted as described for the 22 screening process but protein expression was performed only at 30 ˚C, 250 rpm. Samples were 23 prepared from three biological replicates, using two technical replicates for each. Acid phosphatase 1 activity assay was conducted immediately after the cultivations. Culture supernatants of EPO 2 cultures were clarified by centrifugation and stored at -20 ˚C until analysis. 3
Quantification of IgG and EPO titers and acid phosphatase activity 4
Antibody titers were determined in duplicate measurements with ELISA as specified in [28] . Data 5 was analyzed by using Gen5 (BioTek Winooski, USA) and R software. Statistical analyses were 6
conducted as described in [9] . 7
The acid phosphatase assay was conducted as described in [24] , with the exception that the assay 8 was done at 22 ˚C. The substrate, 20 mM para-nitrophenyl-phosphate in sodium acetate buffer pH 9 4.2, was added to start the reaction. Reaction was terminated after 0, 2, 10, and 20 minutes and 10
absorbance was read at 405 nm with BioTek Synergy 2 spectrophotometer. Relative acid 11
phosphatase activity was determined from the colorimetric product formation as the slope of 12 absorbance versus time. Concentration of EPO was determined with a commercial ELISA-kit 13 (RAB0654, Sigma Aldrich) following the manufacturer's instructions. Absorbance at 450 nm was 14 read with BioTek Synergy 2 spectrophotometer. 15
Shake flask cultivations 16
Strains were inoculated to 5 ml SD-URA-LEU with 2 % glucose and grown overnight at 30 ˚C, 17 250 rpm to ODR 600 R5-10. Ten ODR 600R of cells were collected by centrifugation at 3,000 g for 5 18
minutes and the cell pellet was resuspended in 10 ml of expression media (SD-URA-LEU with 2 19 % galactose) obtaining a starting ODR 600R of 1.0. Strains were cultivated in 250 ml shake flasks in 20 inducing conditions at 30 ˚C, 200 rpm for 24 hours and samples were collected at time points 0, 6, 21 12, and 24 hours. Supernatant samples were collected as follows: 1 or 2 ml was taken from culture, 22
cells were spun down and the supernatant was adjusted to 1xPBT and stored at -20 ˚C until 23 analysis. Resulting cell pellets were resuspended in the same volume of fresh, prewarmed media 1 and returned to the expression culture. Sample collection resulted in culture media replacement at 2 a rate of 1 ml per six hours. ODR 600R was measured with an eppendorf Biophotometer plus -3 spectrophotometer (Eppendorf AG, Hamburg, Germany). IgG titers were measured in 2-3 4
technical replicates as described in [28] . All shake flask cultures were repeated with three 5 biological replicates. To account for the dilution due to addition of fresh media, averaged 6
volumetric productivity
was defined as 7 8 9
Where [AB]R 2R is the measured antibody titer, [ ] 1 is the antibody titer of the previous time point, 10 is the culture volume, is the sample volume taken in the previous time point and 2 and 1 are 11 the time points in hours. 12
10 3 Results 1 3.1 Selected mammalian folding factors were overexpressed in two chassis strains and 2 showed an increase in specific product yields with increasing temperature 3
Guided by studies on plasma cell differentiation and IgG folding, we selected a subset of ER 4 resident folding factors known to be involved in IgG synthesis and folding [29] . We selected two 5
PPIases, FKBP2 and cyclophilin B (CypB), four PDIs (P5, ERp57, ERp72, and PDI), the 6
chaperones BiP and GRP94, and the co-chaperones of BiP, ERdj3 and GRP170. GRP170 has also 7 been reported to have holdase activity, as it binds unfolded proteins directly [30]. All the selected 8
genes are significantly upregulated both at protein and transcript level after four days of B cell 9 differentiation (Supporting information, Table S3 ), as we concluded from our own analysis of 10 microarray data published in [31] and proteomics data reported in [14] . To be able to adjust 11 expression levels of the folding factors, the selected mammalian cDNAs were expressed under 12 control of five different promoters. In order to allow co-expression, the expression constructs were 13 cloned into plasmids with LEU2 and URA3 selection markers resulting in 65 different plasmids 14 (Supporting information, Table S2 ).
15
The plasmids were transformed individually and in combinations into two different IgG producing 16 strains, the nonengineered wt and the ∆opi1 strain, containing the deletion of the OPI1-gene that 17 results in an enlarged ER and significantly higher IgG secretion [9, 32]. To determine the specific 18 product yields of our strains, we used a previously established screening platform described in [9] . 19 We cultivated all strains at 20, 25, and 30 ˚C using 0.5% and 2.0% galactose for induction. Specific 20 product yields (IgG titer normalized by cell density) increased with temperature while the wt and 21
Δopi1 strains remained as two distinct populations (Supporting information, Fig. S1 ). Generally, 22
IgG titers and specific product yields were higher with 0.5 % than with 2 % induction, although 23 the difference in specific product yields was smaller than in titers between the two induction levels 1 (Supporting information, Table S4 , S5). 2 3.2 PPIases and the chaperone BiP with its co-chaperone GRP170 were the most successful 3 folding factors to improve specific product yields 4
In order to identify constructs capable of improving specific product yields, we took the overall 5
performance of the strains with both induction levels into account. By first comparing the strains 6
to the respective background strain within a condition (Supporting information, Table S4 ), we 7
determined the mean fold-change in specific product yield for each construct, as shown in Δopi1 strains. In most cases, expression of folding factors resulted in relatively minor effects, 10 and did not change the specific product yields considerably ( Fig. 1A ). Neither the different 11 molecular functions of proteins nor the promoters allowed separating the tested strains into 12 different groups, indicating that the effect of overexpression of different folding factors remained 13 largely unpredictable. Based on the results from the screening approach, we identified the 14
PPIases FKBP2 and CypB, BiP and its co-chaperone GRP170 as the most interesting candidates, 15
which improved specific product yields up to 1.6-fold. Interestingly, the strains with the co-16
chaperone performed slightly better than those with BiP ( Fig. 1A) . In the Δopi1 strains, the UPR-17
controlled promoters PR KAR2R and PR PDI1R seemed to produce the best level of chaperone expression 18 (Fig. 1A, right panel) . This is in line with our previous observation that these promoters are 19
useful modules in adjusting overexpression of chaperones [9] . In contrast, stronger promoters 20
were responsible for the highest fold-changes in wt strains (Fig. 1A, left panel) , demonstrating 21 that a different level and pattern of expression was required in these two strain backgrounds. 22
Although the highest fold changes were observed at 25 ˚C, the highest IgG titers were observed 1 at 30 ˚C (Supporting information, Table S4 ). 2
The results in Figure 1 show one clear deviation: the wt strain expressing P5 under control of PR GAL1R 3 performed extraordinarily well in antibody secretion. All the measured specific product yields of 4 this strain were above 1.5 -fold, in lower temperatures up to 3.6 -fold ( Fig. 1A , Supporting 5 information, Table S4 ). This strain also had the highest mean IgG titer from all wt samples 6 (Supporting information, Table S4 ). 7 8
Co-overexpression of two folding factors revealed limited benefits of several 9
modifications to ER and folding 10
Based on the reported interactions of the different folding factors [33] depicted in Fig. 2A, we  11 tested all the shown pairs of genes and determined their effect on antibody titers (Fig. 2B) . We 12 selected one or two promoters for each folding factor based on the screening results obtained with 13 the single construct cultivations. In total, we tested 35 different combinations (Supporting 14 information, Table S5 ). For the wt strains, we observed a small shift towards higher antibody titers 15 upon co-expression of two folding factors ( Fig. 2B lower panel compared to Fig. 1B) . In contrast, 16
Δopi1 strains co-expressing two folding factors hardly exceeded the improvement obtained by the 17 OPI1-deletion alone (Fig. 2B) . Generally, the overexpression of a second folding factor in a strain 18 that had already displayed high specific product yield did not result in an additional benefit. 19
The best strains of the two screening sets are summarized in Table 1 , which shows the highest 20 overall specific product yields from both strain backgrounds. In the best producing Δopi1 strains, 21
all folding factors were expressed under control of PR KAR2R and PR PDI1R . Combined with the OPI1-22
gene deletion, GRP170 overexpression led up to 6-fold higher specific product yield compared to 23 the wt (Table 1) . Although the improvement in specific product yield was smaller, the Δopi1 strains 1 expressing FKBP2 or BiP under PR PDIR reached comparable titers to GRP170 overexpression strain, 2 being slightly over 100 µg/l ( Table 1) . None of the strains with simultaneous overexpression of 3 two folding factors was among the ten best strains in the Δopi1 background. In contrast, four of 4 such pairs in the wt background are listed in Table 1 . In addition, the folding factors improving 5 specific product yields in Δopi1 background were noted to be more effective when expressed under 6 stronger promoters in wt (Table 1 ). It is possible that deletion of OPI1 gene already enables the 7 cell to circumvent major portion of the folding bottleneck, whereas the demand for improvement 8 in wt strains is larger and requires a greater amount of folding factors. 9 10
Folding factor overexpression affected only mammalian protein secretion 11
Our main assumption was that the folding factors would improve secreted antibody titers through 12
increasing the folding rate of IgG in the yeast ER, but other cellular effects of folding factor 13 overexpression cannot be excluded. In the case of BiP, we investigated the interaction of this 14 protein with intracellular antibody by co-immunoprecipitation, and confirmed that the antibody 15
interacts with human BiP in the yeast cell (Supporting information, Fig. S2 ). For most other folding 16
factors, we verified their co-expression in yeast and interestingly, their expression levels varied 17
considerably even when expressed under the same promoter (Supporting information, Fig. S3 ).
18
To determine if the folding factors had a general influence on protein production, we tested for 19 their possible effects on the secretion of two additional model proteins. We created strains with 20
and without the OPI1-gene deletion that had an overexpression cassette of the endogenous yeast 21 protein, Pho5p, a secreted acid phosphatase, or of human erythropoietin (EPO), a heavily 22 glycosylated cytokine. Acid phosphatase activities and EPO concentrations were recorded after 23 cultivation in the same conditions as for the IgG titer measurements at 30 ˚C (Table 1) . Although 1 the OPI1-gene deletion increased IgG titers significantly, it halved the amount of secreted acid 2 phosphatase activity in the supernatant (Fig. 3A) . Some of the most interesting folding factor 3 constructs were tested together with Pho5p overexpression (P5, the GRP94/ERp72 pair, BiP, 4 GRP170, and FKPB2, constructs from strains 87, 306, 151, 142 and 124, see Table 1 ), but they 5 had little effect on Pho5p production (Fig. 3A) . Moreover, in contrast to IgG, the differences in 6
induction strength had a clear impact on Pho5p activity; 2 % galactose at least doubled the activity 7
of Pho5p in the supernatant (Fig. 3A) . Overall, the secretion patterns of acid phosphatase and IgG 8
were completely different in the strains tested. When testing expression of EPO, the improvements 9
in the production of this cytokine followed the same trends as observed for IgG secretion ( Figure  10 3B). In addition to the titers shown in Figure 3B , also patterns in specific product yields were 11 comparable with IgG and EPO (data not shown). Overall, the effects of the beneficial 12 modifications identified here seemed to be specific only for the two mammalian glycoproteins 13 tested ( Figure 3 ). Interestingly, increasing induction hampered EPO secretion more than measured 14
for IgG ( Figure 3B ). As secretion of Pho5p could simply be increased with stronger induction, this 15
demonstrates that the secretory pathway is more adapted for the expression of the endogenous 16
protein Pho5p than for IgG and EPO. 17 3.5 Mammalian PPIase FKBP2 displayed similar improvements to the yeast PPIase CPR5 18 We cultivated a selection of strains in shake flasks and followed the production over time to gain 19 more insight into the secretion behavior of these strains. We chose strains expressing BiP, FKBP2, 20
and GRP170 from the Δopi1 strains (numbers 142, 124 and 151), and the strains expressing P5, 21 and the GRP94/ERp72 pair (numbers 87, and 306) from the wt background, as these resulted in 22
the highest improvements in specific product yield in the two backgrounds (Table 1) . Secretion 23 phenotypes of these strains were confirmed in shake flask cultivations, as the IgG titers were 1 comparable to the screening cultures (Fig. 4A, 4B) . We previously reported a yeast PPIase 2 construct, PR GPDR -CPR5, which strongly increased specific antibody yields [9] . As we wanted to 3 compare the two approaches of having a native versus a heterologous folding enhancer, we 4
included this Δopi1 -based strain expressing the native ER localized PPIase in this experiment. 5
Although the Cpr5p-overexpression strain reached the highest titer at 24 hours, the mammalian 6
PPIase FKBP2 expressing strain produced similar titers in a shorter time (Fig. 4B ). When we 7
plotted averaged volumetric productivity against ODR 600R , we noticed that the increase in 8
productivity was accompanied with a shift to lower cell densities, especially in the Δopi1 strains, 9
indicating that high titers were achieved at the expense of culture density (Fig. 4C, 4D ). Thus, 10
although the increase in specific product yield was much greater with overexpression of Cpr5p 11 ([9]) than for FKBP2 (Table 1) , the difference in IgG titer at 24 hours was relatively small. 12
Overexpression of folding factors seemed to improve volumetric productivity especially around 13 the midpoint of the cultivations (Fig. 4C, 4D ). In the wt background, the folding factor expressions 14 actually decreased productivity during the first six hours (Fig. 4C) . Afterwards, the cells seem to 15 adapt to the production phase, as the productivity strongly increases (Fig. 4C) . Interestingly, in the 16 shake flasks, most of the strains reach their maximum IgG titer already at 12 hours after induction 17 (Fig. 4A, 4B ). In accordance to other studies [10] , protein degradation might be a prevalent 18
problem in our yeast system, as the productivity turned to negative values at the last time point 19 (Fig. 4C, 4D) . 20
Discussion 1
Improving folding and secretion of recombinant proteins is a complicated task as the effects of 2 overexpressing folding factors are not straightforward to anticipate and dependent on the target 3 recombinant protein [18, 34] . In contrast to upregulating endogenous folding factors, in this study 4
we explored an alternative approach for folding engineering: we looked at the native environment 5 of the target protein and transferred the antibody-specific folding factors to the selected host. The 6
folding helpers we selected represent each of the different classes of folding factors that interact 7
with the folding heavy and light chain polypeptides [35] . Judging by the reported abundance of 8
interactions with the IgG molecule, human BiP would be the first choice to transfer as a folding 9 enhancer [29]. Although not as successful in shake flasks, co-expression of human BiP was 10
improving the specific product yields of IgG up to 1.5-fold (Table 1) , more than overexpression 11 of the yeast equivalent Kar2p [9, 36]. The PPIase FKBP2 and the chaperone GRP170 were also 12 effective in improving titers, resulting in an up to 6-fold increase in specific product yields when 13
combined with the deletion of OPI1-gene (Table 1, Fig. 4B ). GRP170 is a homolog of yeast co-14 chaperone Lhs1p, but the beneficial effects of GRP170 are most likely to rise from its activity to 15
bind unfolded proteins directly [30] . Although improvements were achieved, the antibody-and 16 plasma cell inspired engineering approach yielded similar results to the host-specific approach. In 17 both cases, the most striking observation was the criticality of the expression levels of the folding 18 factors ( Figure 1A, [9] ). Fine-tuning the expression levels with the selection of promoters did not 19 display much predictability, and the same promoter did not guarantee similar protein levels ( Fig.  20 1A, Supporting information, Figure S3 ). In addition, the combination of folding factors were 21
generally not improving IgG titers to the same extent (Fig. 2B) , probably due to the overload from 22 multiple protein overexpression. For future approaches of ER engineering, the selection of 1 promoters should be broadened, mainly to weaker promoters. 2
PPIases present an intriguing class of factors to improve antibody folding, as specific peptidyl 3 prolyl-isomerizations have been reported to constitute the rate-limiting steps in immunoglobulin 4 fold formation and IgG tetramer assembly [37-39]. In fact, all antibody domains require at least 5 one cis configured proline residue [29] . Lilie et al. [37] reported that the isomerization of Pro159 6
might have been responsible for slow folding of a Fab fragment, which would correspond to 7
Pro157 in our heavy chain. This proline is located in the CR HR 1 domain that is key in the control of 8
IgG assembly [39] . Under normal conditions, ER-specific PPIase activity in S. cerevisiae is barely 9
needed [40], so upregulating PPIase activity seems to be crucial for improving IgG titers in yeast.
10
The two mammalian PPIases CypB and FKBP2 were both successful in improving specific 11 product yields and IgG titers (Table 1, Figure 4) , although not to the same extent as the yeast 12
PPIase Cpr5p ( Figure 4B ). It is possible that Cpr5p acts on several of the proline residues, while 13 it has been shown for CypB and FKBP2 that they have differential substrate specificity limited to 14 certain peptidyl-prolyl isomerizations of antibodies [37] . 15 Although we demonstrated that at least BiP interacts with IgG in yeast (Supporting information, 16 Figure S2 ), the effects of the constructs might partially results from pleiotropic effects. For 17 example, the wt strain Y87 with PR GALR -P5 expression cassette was an outlier in our screening 18 experiments ( Figure 1A) . P5 was the only folding factor that was expressed with a yeast-derived 19 leader peptide, and interestingly, the folding factor showed significant effects only when expressed 20 under PR GAL1R . A possible scenario for a pleiotropic effect would be the overload of the translocation 21 machinery. Perhaps the yeast-derived leader peptide in combination with a strongly induced 22
promoter resulted in P5, light and heavy chains competing with each other for availability of 23 translocation machinery. Overloading the translocation step might explain the initial decrease in 1 productivity in the wt-based strains expressing P5, or the GPR94/ERp72 pair (Fig. 4A, 4C ). If 2 translocation is initially slowed down, the passing heavy and light chains might have more space 3 available in the ER to assemble and exit while overloading of ER is circumvented. Transit through 4
the ER has been shown to determine the limits of secretion capacity [41], so effectively reducing 5 the translocation rates of target proteins might prevent protein accumulation and lead to increase 6 in secretion. Clearly, events related to the ER seem to be most crucial in determining the speed of 7
IgG secretion and are likely rate limiting also for secretion of the other mammalian recombinant 8 glycoprotein tested, EPO ( Figure 3B ). 9
Co-overexpressing mammalian folding factors together with human antibodies proved to be an 10
interesting alternative to engineering the yeast host for improved IgG secretion, although the native 11
folding factor Cpr5p remained superior to heterologous folding factors. Nevertheless, several of 12 the mammalian proteins were successful in improving titers and it would be interesting to 13 determine how these improvements transfer to the fermentation scale. In any case, our antibody 14 titers of up to 100 µg/l are very modest compared to the commercially employed mammalian cell 15 lines, working with titers up to g/l scale [42] . Use of the IgG's native folding helpers could display 16
better transferability between production systems, so our approach could be adopted for 17 engineering other expression hosts as well. proportional in approximately 1:5.5 ratio to measurements with regular path length of 1 cm. 4 were normalized to the control in the respective condition and the means of the two 5
induction conditions were used. The corresponding IgG titers are depicted as distribution 6
plots at the three temperatures in (B) for all wt strains and (C) for all Δopi1 strains. The 7 y-axis is proportional to relative frequency and the range of the measured IgG titers is 8
given in the x-axis. The area under each curve is equal to 1. 9 Figure 2 : Co-expression of folding factor pairs. The selected chaperones are shown to 10 interact with each other and their reported primary associations [33] are summarized in 11 (A). All folding factor pairs connected by lines in (A) were tested and the mean fold-12 changes and distribution of IgG titers of each strain in each condition are shown in (B). 13
Fold-changes were calculated from specific product yields (titer normalized by ODR 600R ). samples. The y-axis is proportional to relative frequency and the range of the measured 20
IgG titers is given in the x-axis. The area under each curve is equal to 1. Each data point 21
represents the mean of at least three biological replicates, each with two technical 22
replicates. 23
Figure 3: Modifications leading to high IgG titers improved EPO secretion but had no 1
effect on acid phosphatase titers. IgG titers were contrasted to (A) secreted acid 2 phosphatase and (B) human EPO secretion in wt, Δopi1, and several folding factor 3 overexpression strains. BiP, GRP170, and FKBP2 were expressed under PR PDIR in the Δopi1 4 background, while constructs in the wt strains were P5-PR GAL1 Rand the GRP94-PR PDIR / 5
ERp72-PR TEFR pair. Protein yields were measured from identical culture conditions, both 6 with 0.5 % and 2 % galactose induction. Acid phosphatase activity is described with 7 arbitrary units. Means of three biological replicates, each with two technical replicates, 8 are shown. 
